

Caitlin W Elgarten

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3580345/publications.pdf>

Version: 2024-02-01

23
papers

98
citations

1478505

6
h-index

1474206

9
g-index

26
all docs

26
docs citations

26
times ranked

89
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of bacterial bloodstream infection does not vary by central-line type during neutropenic periods in pediatric acute myeloid leukemia. <i>Infection Control and Hospital Epidemiology</i> , 2023, 44, 222-229.	1.8	1
2	Early stool microbiome and metabolome signatures in pediatric patients undergoing allogeneic hematopoietic cell transplantation. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29384.	1.5	8
3	Improving Guideline-Congruent Care for Chemotherapy-Induced Nausea and Vomiting Prophylaxis in Pediatric Oncology Patients. <i>JCO Oncology Practice</i> , 2022, 18, e412-e419.	2.9	2
4	Unrelated donor $\hat{\pm}$ T cell ⁺ and B cell ⁺ depleted HSCT for the treatment of pediatric acute leukemia. <i>Blood Advances</i> , 2022, 6, 1175-1185.	5.2	9
5	Identifying relapses and stem cell transplants in pediatric acute lymphoblastic leukemia using administrative data: Capturing national outcomes irrespective of trial enrollment. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28315.	1.5	1
6	Broad-Spectrum Antibiotics and Risk of Graft-versus-Host Disease in Pediatric Patients Undergoing Transplantation for Acute Leukemia: Association of Carbapenem Use with the Risk of Acute Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 177.e1-177.e8.	1.2	16
7	Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29026.	1.5	11
8	Presentation acuity, induction mortality, and resource utilization in infants with acute leukemia. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28940.	1.5	1
9	Incidence of CMV Infection and Disease and Adverse Events Associated with Antiviral Therapy in a Retrospective Cohort of Allogeneic Hematopoietic Cell Transplant Recipients at an Academic Children's Hospital. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 910-918.	1.3	5
10	Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29281.	1.5	6
11	Ex Vivo T-Cell Receptor $\hat{\pm}$ +/CD19 +depletion of Peripheral Stem Cell Grafts for Pediatric Patients with Bone Marrow Failure (BMF) Undergoing Unrelated Donor Transplantation. <i>Blood</i> , 2021, 138, 171-171.	1.4	0
12	Pediatric Patients with Immune Thrombocytopenic Purpura Have a Dysbiotic Gut Microbiome at Time of Diagnosis. <i>Blood</i> , 2021, 138, 3169-3169.	1.4	1
13	1745. Retrospective Cohort Analysis to Determine the Incidence of CMV Infection and Disease in Allogeneic Hematopoietic Cell Transplant Recipients at an Academic Children's Hospital. <i>Open Forum Infectious Diseases</i> , 2019, 6, S639-S640.	0.9	0
14	Early Broad-Spectrum Antibiotics and Risk of Acute Graft-Versus-Host Disease in Children: An Analysis from the Center for International Blood and Marrow Transplantation Research (CIBMTR) and the Pediatric Health Information System (PHIS). <i>Blood</i> , 2019, 134, 599-599.	1.4	0
15	Outcomes of matched sibling donor bone marrow transplantation in children using single-agent calcineurin inhibitors as prophylaxis for graft versus host disease. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26726.	1.5	7
16	Successful treatment of pulmonary mucormycosis in two pediatric hematopoietic stem cell transplant patients. <i>Pediatric Transplantation</i> , 2018, 22, e13270.	1.0	3
17	Hospital-Level Variability in Broad-Spectrum Antibiotic Use for Children With Acute Leukemia Undergoing Hematopoietic Cell Transplantation. <i>Infection Control and Hospital Epidemiology</i> , 2018, 39, 797-805.	1.8	6
18	Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 959-971.	2.4	19

#	ARTICLE	IF	CITATIONS
19	Assessing Neighborhood Characteristics As Risk Factors for Bloodstream Infection in Children with Acute Leukemia. <i>Blood</i> , 2018, 132, 833-833.	1.4	0
20	Using Administrative Data to Identify Relapse and Hematopoietic Stem Cell Transplantation (HSCT) in Children with Acute Lymphoblastic Leukemia (ALL): Validation at Two Centers and Incidence Estimation in a National Cohort. <i>Blood</i> , 2018, 132, 624-624.	1.4	0
21	A Novel Approach to Identifying Septic Shock (SS) in Children with Acute Lymphoblastic Leukemia (ALL) Using Pediatric Health Information System (PHIS) Data: Methods Validation and Incidence Estimation in a National Cohort. <i>Blood</i> , 2018, 132, 3597-3597.	1.4	0
22	Evaluation of Hospital Admission Patterns in Children Receiving Treatment for Acute Lymphoblastic Leukemia: What Does a Typical Leukemia Experience Look like?. <i>Blood</i> , 2018, 132, 4763-4763.	1.4	2
23	Comparative Effectiveness of Rasburicase and Allopurinol in Children with Acute Lymphoblastic Leukemia: An Emulated Pragmatic Trial Using Observational Data. <i>Blood</i> , 2018, 132, 830-830.	1.4	0